
Superpower peptides available for pre-order. Get first access.

Peptide science
What are the side effects of tesofensine?
Tesofensine side effects in trials included higher heart rate and blood pressure, dry mouth, nausea, and insomnia. See Phase 2 data and how dose changes risk.
Quick answer
In trials, tesofensine commonly caused dry mouth, nausea, constipation, and insomnia. It also raised heart rate by 7.4 beats per minute at 0.5 mg. Side effects grew more common at higher doses, and some participants reported depressed mood. A single-dose study of 52 stimulant users found no difference from placebo on abuse measures. Tesofensine is not FDA-approved, so published side effect data come from research settings.
- Published
- November 10, 2026
- Last updated
- November 10, 2026
Tesofensine side effects across clinical trials
In clinical trials, the investigational drug tesofensine raised heart rate and blood pressure and commonly caused dry mouth, nausea, constipation, and insomnia. Side effects grew more common at higher doses. Tesofensine is not FDA-approved and remains under regulatory review1. Published data on tesofensine side effects come from research settings, where trials tracked heart rate and blood pressure alongside reported symptoms.
Tesofensine raised heart rate and blood pressure in trials
Tesofensine raised heart rate in a dose-dependent way2 in trials, and blood pressure rose significantly at the top dose, 1 mg3.
In a 24-week Phase 2 trial of 203 adults with obesity, heart rate rose by 7.4 beats per minute at 0.5 mg4. Blood pressure did not rise significantly at 0.25 or 0.5 mg4. The journal that published this trial issued an expression of concern about it4 in 2013.
In rats, tesofensine raised heart rate and blood pressure by increasing sympathetic (fight-or-flight) nervous system activity5, and the beta-blocker metoprolol blocked that rise. Tesomet, an investigational combination, pairs tesofensine 0.5 mg with metoprolol 50 mg6. In a 24-week trial of 21 adults with hypothalamic obesity (obesity after hypothalamic injury), heart rate and blood pressure showed no significant difference from placebo6. The Tesomet trial still recorded side effects like those seen in earlier tesofensine trials.
Common tesofensine side effects and mood changes
The most common tesofensine side effects4 in trials were dry mouth, sleep problems, and digestive effects such as nausea and constipation.
| Side effect | Phase 2 obesity trial (203 adults, 24 weeks) | Tesomet trial (21 adults with hypothalamic obesity, 24 weeks) |
| Dry mouth | Among the most common effects4 | 43% vs 0% on placebo6 |
| Sleep disturbance or insomnia | Among the most common effects | 50% vs 13% on placebo6 |
| Headache | More than 25% at all doses3 | 36% vs 0% on placebo6 |
| Nausea | Among the most common effects | 2 of 14 vs 2 of 87 on placebo |
| Constipation, hard stools, or diarrhea | Among the most common effects | Constipation and hard stools 2 of 14 each vs 0 of 87; diarrhea 0 of 14 vs 2 of 87 |
| Dizziness | Rate not reported | 6 of 14 vs 3 of 87 on placebo |
Insomnia was the most common side effect8 among weight-loss drugs that act on brain monoamines (chemical messengers such as dopamine and serotonin), tesofensine included. At 0.5 mg, tesofensine increased depressed mood9 in the obesity trial. Tesofensine may increase psychiatric disorders9 more broadly.
In the Tesomet trial of 21 adults with hypothalamic obesity, a serious worsening of pre-existing anxiety led one participant to stop treatment6. Across treatment trials in hypothalamic obesity, side effects were mostly mild to moderate10.
At higher doses, tesofensine also blocks up to 77% of dopamine transporters11 in the brain, a property that raises the question of misuse.
What a single-dose study found on tesofensine abuse potential
In a single-dose, randomized, double-blind crossover study of 52 recreational stimulant users, tesofensine's effects on subjective measures did not differ significantly from placebo12. D-amphetamine, the stimulant used as a positive control, scored significantly higher than placebo on every primary measure.
The study followed one dose for 48 hours, so it cannot show whether daily, long-term use carries a risk of dependence. Longer trials gave tesofensine daily for weeks, and their side effects rose with the dose.
Higher tesofensine doses brought more side effects
Tesofensine side effects became more frequent as the dose went up13. In a 14-week trial in advanced Parkinson's disease, digestive and neuropsychiatric side effects exceeded placebo rates, most of all at higher doses.
In four 14-week trials in which 740 adults with Parkinson's or Alzheimer's disease took tesofensine, heart rate rose from 2.1 to 6.8 beats per minute14 as the dose climbed. A faster heart rate was common at 1 mg15 in 261 adults with early Parkinson's disease. In the obesity trial, mood changes increased at 1 mg3.
Tesofensine clears slowly, with a half-life of roughly 234 hours16 in adults with Alzheimer's disease. The longest published follow-up is 48 weeks of Tesomet treatment17 in adults with hypothalamic obesity, so data on years of use are missing. Each figure also comes from trial-grade tesofensine at fixed doses.
Tesofensine sold online is not an approved product
Tesofensine is marketed online as a dietary supplement1, even though it is not an approved medicine. Of 776 supplements flagged in FDA warnings for hidden drug ingredients from 2007 to 2016, 40.9% were sold for weight loss18.
Product quality outside trials goes unverified, so published trial data remain the most reliable record of tesofensine's effects.
Where can I learn about peptides?
Superpower’s peptide library explains investigational compounds such as tesofensine alongside peptides studied for weight and metabolism. The library's articles set out what trials recorded, side effects included.
Health journalists and licensed clinicians share the writing and fact-checking of each one. Tesofensine acts on brain chemistry instead of mimicking a peptide hormone, a contrast the science behind peptides makes clearer.
IMPORTANT SAFETY INFORMATION
Tesofensine is NOT FDA-approved for any indication in the United States. No US NDA exists and no active US Phase III program is ongoing as of November 2026. Tesofensine is not approved in Mexico, where a COFEPRIS application is pending, and it is not available in the United States through any approved US medical channel. Superpower Health does not prescribe, sell, compound, or facilitate access to tesofensine. This article is provided for educational and informational purposes only.
Tesofensine should not be used by anyone in the United States outside an IRB-approved clinical research study; there is no US-approved indication and no contraindication table because there is no approved US use. Populations of particular pharmacological concern based on trial exclusion criteria include: uncontrolled hypertension; history of major cardiovascular events (myocardial infarction, stroke, arrhythmia); active or unstable psychiatric disorder; history of substance use disorder; pregnancy or breastfeeding; concurrent MAOIs or other serotonergic medications.
Warnings: blood pressure elevation (dose-dependent; significant at 1 mg in trials); heart rate elevation (sympathomimetic, dose-dependent); psychiatric adverse events including mood disturbance and insomnia; serotonin syndrome risk with concomitant serotonergic agents; dopaminergic activation with potential neuropsychiatric effects. Long-term safety data are limited; no US regulatory pharmacovigilance program exists.
Common side effects reported in trials: dry mouth; nausea; constipation; insomnia; elevated blood pressure; elevated heart rate; mood changes.
Gray-market sourcing of tesofensine in the United States (through unregulated compounders, offshore suppliers, or research chemical vendors) carries significant and unquantifiable risk: no US manufacturing oversight, no quality assurance, no pharmacovigilance, and potential legal liability. Superpower strongly discourages sourcing tesofensine through any non-approved channel.
No FDA-approved prescribing information exists. For registered clinical trial information, see ClinicalTrials.gov19.
This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to tesofensine. Tesofensine is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.